Asif A. Sharfuddin

Asif A. Sharfuddin

Auto-generated profile, based on publicly available information

Asif A. Sharfuddin

Department of Nephrology, Indiana University School of Medicine, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ASAsif Sharfuddin
Asif Sharfuddin
Kidney transplantation can be associated with various complications that vary from vascular complications to urologic disorders to immunologic adverse effects. In evaluating the recipient with graft dysfunction, clinicians can choose among several imaging modalities, including ultrasonography, nuclear medicine studies, computed tomography, and magnetic resonance imaging. This review discusses the evaluation of the kidney transplant recipient using these imaging procedures, emphasizing the clinical diagnostic utility and role of each modality. A kidney biopsy is often required as a gold standard for diagnostic purposes. However, because of the inherent risks of a kidney biopsy, noninvasive imaging in diagnosing causes of graft dysfunction is a highly desired tool used and needed by the transplant community. Because the diagnostic accuracy varies depending on the time course and nature of the transplant-related complication, this review also addresses the advantages and limitations of each modality. The recent advances in kidney transplant imaging techniques and their clinical implications are also discussed.

1 March 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CTChristie P. Thomas
Christie P. Thomas
RDReem Daloul
Reem Daloul
KLKrista L Lentine
Krista L Lentine
RGReginald Gohh
Reginald Gohh
PAPrince Mohan Anand
Prince Mohan Anand
YCYasar Caliskan
Yasar Caliskan
The growing accessibility and falling costs of genetic sequencing techniques has expanded the utilization of genetic testing in clinical practice. For living kidney donation, genetic evaluation has been increasingly used to identify genetic kidney disease in potential candidates, especially in those of younger ages. However, genetic testing on asymptomatic living kidney donors remains fraught with many challenges and uncertainties. Not all transplant practitioners are aware of the limitations of genetic testing, are comfortable with selecting testing methods, comprehending test results, or providing counsel, and many do not have access to a renal genetic counselor or a clinical geneticist. Although genetic testing can be a valuable tool in living kidney donor evaluation, its overall benefit in donor evaluation has not been demonstrated and it can also lead to confusion, inappropriate donor exclusion, or misleading reassurance. Until more published data become available, this practice resource should provide guidance for centers and transplant practitioners on the responsible use of genetic testing in the evaluation of living kidney donor candidates.

28 December 2015 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
AKAli Khalil
Ali Khalil
MMMuhammad A. Mujtaba
Muhammad A. Mujtaba
TTTim E. Taber
Tim E. Taber
MYMuhammad Sohail Yaqub
Muhammad Sohail Yaqub
WGWilliam Goggins
William Goggins
ASAsif A. Sharfuddin
Asif A. Sharfuddin

29 April 2014 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
ADAlejandro Diez
Alejandro Diez
JPJohn Powelson
John Powelson
CSChandru P. Sundaram
Chandru P. Sundaram
TTTim E. Taber
Tim E. Taber
MMMuhammad A. Mujtaba
Muhammad A. Mujtaba
ASAsif A. Sharfuddin
Asif A. Sharfuddin

12 March 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ACAnil Chandraker
Anil Chandraker
ARAnil Regmi
Anil Regmi
RGReginald Gohh
Reginald Gohh
ASAkhil Sharma
Akhil Sharma
EWE. Steve Woodle
E. Steve Woodle
DWDavid Wojciechowski
David Wojciechowski
Key Points: Posoleucel was generally safe, well tolerated, and associated with a greater reduction of BK viremia compared with placebo. BK viremia reduction occurred coincident with an increase in the circulating frequency of BK virus–specific T cells in posoleucel recipients. The presence and persistence of posoleucel was confirmed by T-cell receptor variable β sequencing. Background: Kidney transplant recipients with BK virus infection are at risk of developing BK virus–associated nephropathy, allograft rejection, and subsequent graft loss. There are no approved treatments for BK virus infection. Posoleucel is an off-the-shelf, allogeneic, multivirus-specific T-cell investigational therapy targeting BK virus, as well as five other opportunistic viruses: adenovirus, cytomegalovirus, Epstein–Barr virus, human herpesvirus 6, and John Cunningham virus. Methods: In this phase 2, double-blind study, kidney transplant recipients with BK viremia were randomized 1:1:1 to receive posoleucel weekly for 3 weeks and then every 14 days (bi-weekly dosing) or every 28 days (monthly dosing) or placebo for 12 weeks. Participants were followed for 12 weeks after completing treatment. The primary objective was safety; the secondary objective was plasma BK viral load reduction. Results: Sixty-one participants were randomized and dosed. Baseline characteristics were similar across groups. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. The proportion of patients who had adverse events (AEs) judged by the investigators to be treatment-related was slightly lower in recipients of posoleucel: 20% (4 of 20 patients) and 18% (4 of 22) in those infused on a bi-weekly and monthly schedule, respectively, and 26% (5 of 19) in placebo recipients. None of the grade 3–4 AEs or serious AEs in any group were deemed treatment-related. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. Three participants had allograft rejection, but none were deemed treatment-related by investigators. In posoleucel recipients, BK viremia reduction was associated with an increase in the circulating frequency of BK virus–specific T cells, and the presence and persistence of posoleucel was confirmed by T-cell receptor sequencing. Conclusions: Posoleucel was generally safe, well tolerated, and associated with a larger reduction of BK viremia compared with placebo. Limitations of this study include the relatively short duration of follow-up and lack of power to detect significant differences in clinical outcomes. Clinical Trial registry name and registration number: Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia, NCT04605484.

20 September 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
NGNeetika Garg
Neetika Garg
CTCarrie Thiessen
Carrie Thiessen
PRPeter P. Reese
Peter P. Reese
MCMatthew Cooper
Matthew Cooper
RLRuthanne Leishman
Ruthanne Leishman
DMDidier Mandelbrot
Didier Mandelbrot
Kidney paired donation (KPD) is a major innovation that is changing the landscape of kidney transplantation in the United States. We used the 2006 - 2021 United Network for Organ Sharing data to examine trends over time. KPD is increasing, with one in 5 living donor kidney transplants (LDKT) in 2021 facilitated by KPD. The proportion of LDKT performed via KPD was comparable for non-Whites and Whites. An increasing proportion of KPD transplants is going to non-Whites. End-chain recipients are not identified in the database. To what extent these trends reflect how end-chain kidneys are allocated, as opposed to increase in living donation among minorities, remains unclear. Half the LDKT in 2021 in sensitized (PRA ≥80%) and highly sensitized (PRA ≥98%) groups occurred via KPD. Yet, the proportion of KPD transplants performed in sensitized recipients has declined since 2013, likely due to changes in the deceased donor allocation policies and newer KPD strategies such as compatible KPD. In 2021, 40% of the programs reported not performing any KPD transplants. Our study highlights the need for understanding barriers to pursuing and expanding KPD at the center level, and the need for more detailed and accurate data collection at the national level.